Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - flucloxacillin sodium monohydrate, quantity: 27.2 mg/ml (equivalent: flucloxacillin, qty 25 mg/ml) - oral liquid, powder for - excipient ingredients: ammonium glycyrrhizinate; sodium benzoate; sucrose; saccharin sodium; disodium edetate; sodium citrate; erythrosine; flavour - for the treatment of confirmed or suspected staphylococcal and other gram-positive coccal infections. indications include pneumonia, osteomyelitis, skin and skin structure and wound infections, infected burns and cellulitis.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - flucloxacillin sodium monohydrate, quantity: 54.4 mg/ml (equivalent: flucloxacillin, qty 50 mg/ml) - oral liquid, powder for - excipient ingredients: erythrosine; sodium citrate; sodium benzoate; sucrose; ammonium glycyrrhizinate; disodium edetate; saccharin sodium; flavour - for the treatment of confirmed or suspected staphylococcal and other gram-positive coccal infections. indications include pneumonia, osteomyelitis, skin and skin structure and wound infections, infected burns and cellulitis.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - morphine hydrochloride trihydrate, quantity: 10 mg/ml - oral liquid, solution - excipient ingredients: citric acid; water for injections; sodium methyl hydroxybenzoate; disodium edetate; glycerol; sodium citrate dihydrate - ordine oral solution is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - morphine hydrochloride trihydrate, quantity: 5 mg/ml - oral liquid, solution - excipient ingredients: sodium citrate dihydrate; citric acid; sodium methyl hydroxybenzoate; glycerol; water for injections; disodium edetate - ordine oral solution is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - morphine hydrochloride trihydrate, quantity: 2 mg/ml - oral liquid, solution - excipient ingredients: sodium methyl hydroxybenzoate; glycerol; sodium citrate dihydrate; water for injections; disodium edetate; citric acid - ordine oral solution is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - morphine hydrochloride trihydrate, quantity: 1 mg/ml - oral liquid, solution - excipient ingredients: disodium edetate; glycerol; water for injections; sodium methyl hydroxybenzoate; citric acid; sodium citrate dihydrate - ordine oral solution is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - ranitidine hydrochloride, quantity: 16.8 mg/ml (equivalent: ranitidine, qty 15 mg/ml) - oral liquid - excipient ingredients: hypromellose; ethanol; sorbitol solution (70 per cent) (non-crystallising); butyl hydroxybenzoate; saccharin sodium; propyl hydroxybenzoate; sodium chloride; dibasic sodium phosphate; monobasic potassium phosphate; purified water; flavour - short-term treatment of proven duodenal ulcer and gastric ulcer, including intravenous use for prophylaxis against recurrent haemorrhage: maintenance treatment to reduce the risk of relapse in duodenal ulcer: maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer: treatment of gastrinoma (zollinger-ellison syndrome): short-term treatment of severe reflux oesophagitis: treatment of scleroderma oesophagitis. the intravenous injection is indicated where oral treatment is inappropriate. new indications as at 2 november 1993: 1. short-term treatment of proven duodenal ulcer and gastric ulcer, including intravenous use for prophylaxis against recurrent haemorrhage. 2. maintenance treatment to reduce the risk of relapse in duodenal ulcer. 3. maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. 4. treatment of gastrinoma (zollinger-ellison syndrom

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - levetiracetam, quantity: 100 mg/ml - oral liquid, solution - excipient ingredients: maltitol solution; purified water; citric acid monohydrate; glycerol; methyl hydroxybenzoate; propylene glycol; sodium citrate dihydrate; acesulfame potassium; propyl hydroxybenzoate; ammonium glycyrrhizinate; flavour - use in epileptic patients aged 4 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation; monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy; add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme); and add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (ige).

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - rivastigmine hydrogen tartrate, quantity: 3.2 mg/ml (equivalent: rivastigmine, qty 2 mg/ml) - oral liquid, solution - excipient ingredients: citric acid; sodium citrate dihydrate; purified water; sodium benzoate; quinoline yellow - exelon is indicated for the treatment of patients with mild to moderately severe dementia of the alzheimer's type.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - fluconazole, quantity: 10 mg/ml - oral liquid, powder for - excipient ingredients: sucrose; citric acid; sodium citrate dihydrate; sodium benzoate; xanthan gum; colloidal anhydrous silica; titanium dioxide; flavour - indications as at 21 may 2004 : diflucan, given orally, is indicated for: 1. treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note : data suggest that the clinical efficacy of diflucan is lower than that of amphotericin b in the treatment of the acute phase of cryptococcal meningitis. 2. maintenance therapy to prevent relapse of cryptococcal meningitis in patients with aids. 3. treatment of oropharyngeal and oesophageal candidiasis in aids and other immunosuppressed patients. 4. secondary prophylaxis of oropharyngeal candidiasis in patients with hiv infection. 5. serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note : it remains to be shown that diflucan is as effective as amphotericin b in the treatment of serious and life-threatening candida infections. until such data are available, amphotericin b remains the drug of choice. 6. vaginal candidiasis when topical therapy has failed. 7. treatment of extensive tinea corporis, extensive tinea cruris and extensive tinea pedis infections in immunocompetent patients in whom topical therapy is not a practical treatment option. usually, topical therapy should be attempted first because oral therapy has a less favourable ratio of benefits to risks (see adverse reactions). diflucan iv is indicated for the same conditions in adults and children but should be used only when diflucan cannot be administered orally.